Four years' experience with an interlaboratory comparison program involving first-trimester markers of down syndrome

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 11, 2010, Pages 1685-1691

  Palomaki, Glenn E ^a   Knight, George J ^a   Lambert Messerlian, Geralyn ^a   Canick, Jacob A ^a   Haddow, James E ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ARTICLE; BLOOD; DOWN SYNDROME; FEMALE; FIRST TRIMESTER PREGNANCY; HEALTH CARE QUALITY; HUMAN; LABORATORY; METHODOLOGY; PREGNANCY; PRENATAL DIAGNOSIS; STANDARD;

BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FEMALE; HUMANS; LABORATORIES; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; QUALITY ASSURANCE, HEALTH CARE;

EID: 78149279109     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Palomaki GE, Knight GJ, McCarthy JE, Haddow JE, Donhowe JM. Maternal serum screening for Down syndrome in the United States: a 1995 survey. Am J Obstet Gynecol. 1997;176(5):1046-1051.
2. Wadsworth Center, New York State Department of Health. Clinical laboratory evaluation program. http://www.wadsworth.org/labcert/clep/PT/fedm/ index.htm. Accessed December 17, 2009.
3. Pandya PP, Snijders RJ, Johnson SP, De Lourdes Brizot M, Nicolaides KH. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. Br J Obstet Gynaecol. 1995;102(12): 957-962.
4. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med. 1999;341(7):461-467.
5. Knight GJ, Palomaki GE, Neveux LM, et al. Integrated serum screening for Down syndrome in primary obstetric practice. Prenat Diagn. 2005;25(12):1162- 1167.
6. Palomaki GE, Steinort K, Knight GJ, Haddow JE. Comparing three screening strategies for combining first- and second-trimester Down syndrome markers. Obstet Gynecol. 2006;107(2, pt 1):367-375.
7. Morris J, Wald N. Down syndrome fetal loss rate in early pregnancy. Prenat Diagn. 2000;20(8):685-686.
8. Hadlock FP, Shah YP, Kanon DJ, Lindsey JV. Fetal crown-rump length: reevaluation of relation to menstrual age (5-18 weeks) with high-resolution realtime US. Radiology. 1992;182(2):501-505.
9. Robinson HP, Fleming JE. A critical evaluation of sonar "crown-rump length " measurements. Br J Obstet Gynaecol. 1975;82(9):702-710.
10. Daya S. Accuracy of gestational age estimation by means of fetal crownrump length measurement. Am J Obstet Gynecol. 1993;168(3, pt 1):903-908.
11. The Fetal Medicine Foundation. Fetal Medicine Foundation scanning protocols. http://www.fetalmedicineusa.com/accredits.php#NT. Accessed December 17, 2009.
12. Nuchal Translucency Quality Review Program. Nuchal Translucency Quality Review operational guidelines. https://www.ntqr.org/SM/Documentation/ NTQROperationalGuidelines.pdf. Accessed December 17, 2009.
13. Wapner R, Thom E, Simpson JL, et al. First-trimester screening for trisomies 21 and 18. N Engl J Med. 2003;349(15):1405-1413.
14. Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med. 2005;353(19):2001-2011.
15. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen. 2003;10(2):56-104. (Pubitemid 36734906)
16. Palomaki GE, Lee JE, Canick JA, McDowell GA, Donnenfeld AE. Technical standards and guidelines: prenatal screening for Down syndrome that includes first-trimester biochemistry and/or ultrasound measurements. Genet Med. 2009; 11(9):669-681.
17. Palomaki GE, Neveux LM, Donnenfeld A, et al. Quality assessment of routine nuchal translucency measurements: a North American laboratory perspective. Genet Med. 2008;10(2):131-138.
18. Neveux LM, Palomaki GE, Larrivee DA, Knight GJ, Haddow JE. Refinements in managing maternal weight adjustment for interpreting prenatal screening results. Prenat Diagn. 1996;16(12):1115-1119.
19. Pangas SA, Woodruff TK. Production and purification of recombinant human inhibin and activin. J Endocrinol. 2002;172(1):199-210.
20. Krantz DA, Hallahan TW, Orlandi F, Buchanan P, Larsen JW Jr, Macri JN. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol. 2000;96(2):207-213.
21. Orlandi F, Damiani G, Hallahan TW, Krantz DA, Macri JN. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency. Ultrasound Obstet Gynecol. 1997;10(6):381-386.
22. Palomaki GE, Neveux LM, Knight GJ, Haddow JE, Lee J. Estimating firsttrimester combined screening performance for Down syndrome in dried blood spots versus fresh sera. Genet Med. 2007;9(7):458-463.